Ultragenyx Pharmaceutical (RARE) stock
NASDAQ
As of the Nov 17, 2026 close (U.S. Eastern)
- Market cap
- $1.7B
- As of Nov 17, 2026
- P/E
- -3.25x
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- 2.33x
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
- Market cap
- $1.7B
- As of Nov 17, 2026
- P/E
- -3.25x
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- 2.33x
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-3.25x
Net loss — not comparable
P/B
—
P/S
2.33x
Earnings and dividend metrics▾
Earnings
EPS
-$5.14
Earnings per share
BPS
—
Book value per share
ROE
—
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $5.14 per share.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 8.1% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $160M+8.1%
$139M
Jul–Sep '24
$160M
Jul–Sep '25
$173M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 4, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 8.1% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 4, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Horn HowardChief Financial Officer · Oct 15, 2026Open-market sale7,066 shares · $108KAvg. price $15.2789,229 shares held after
- Huizenga Theodore AlanSVP, Chief Accounting Officer · Sep 15, 2026Open-market sale1,283 shares · $17KAvg. price $13.5767,863 shares held after
- Huizenga Theodore AlanSVP, Chief Accounting Officer · Sep 3, 2026Open-market sale161 shares · $2KAvg. price $13.9969,146 shares held after
- Horn HowardChief Financial Officer · Aug 3, 2026Open-market sale4,696 shares · $117KAvg. price $24.9296,295 shares held after
- Parschauer Karah HerdmanEVP and Chief Legal Officer · Aug 3, 2026Open-market sale1,900 shares · $47KAvg. price $24.9292,562 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Ultragenyx Pharmaceutical (RARE) stock information
NASDAQ
Ultragenyx Pharmaceutical (RARE) is listed on NASDAQ. Its market capitalization is about $1.7B. On trailing-twelve-month earnings the P/E ratio is -3.25. These figures are computed in-house from official filings and are reference information only.
Ultragenyx Pharmaceutical — frequently asked questions
- What is the P/E ratio of Ultragenyx Pharmaceutical (RARE)?
- On a trailing-twelve-month basis, RARE trades at a P/E ratio of -3.25. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Ultragenyx Pharmaceutical?
- RARE has a market capitalization of about $1.7B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.